Analyst consensus rating
Fulcrum Therapeutics Analyst Rating: Hold
FULC is rated Hold by 4 analysts with a $3.50 target. As of 2026-08-28.
Direct answer
Fulcrum Therapeutics's consensus rating is Hold.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.50.
Forecast evidence checked August 28, 2026.
Get free Fulcrum Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.85
- Average price target
- $3.50
- High price target
- $4.00
- Low price target
- $3.00
- Low target gap
- -22.1%
- Target upside
- -9.1%
- High target gap
- +3.9%
- Target range width
- 26%
- Consensus rating
- Hold
- Analysts
- 4
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Fulcrum Therapeutics?
Fulcrum Therapeutics has a verified Hold consensus. The same dataset has an average price target of $3.50.
How far are Fulcrum Therapeutics's low and high targets from the recorded price?
The low target implies -22.1%, while the high target implies +3.9%.
How many analysts are included in Fulcrum Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Fulcrum Therapeutics's target upside or downside calculated?
The average target of $3.50 is divided by the recorded price of $3.85, then one is subtracted to produce -9.1%. This does not guarantee a future return.
When was Fulcrum Therapeutics's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.